Rein TherapeuticsRNTX +3.12%30 Operating Margin % is 0.00% as of Mar. 2026. GuruFocus rates RNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Rein Therapeutics ranks worse than 105820% on this metric.
The historical rank and industry rank for Rein Therapeutics's Operating Margin % or its related term are showing as below:
RNTX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.77 * Ranked among companies with meaningful Operating Margin % only.
Rein Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Rein Therapeutics (NAS:RNTX) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Rein Therapeutics Operating Margin % Related Terms
Rein Therapeutics Operating Margin % Historical Data
* Premium members only.
The historical data trend for Rein Therapeutics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNTX vs ATRA, OSTX, IBIO: Operating Margin % Comparison
For the Biotechnology subindustry, Rein Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rein Therapeutics Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Rein Therapeutics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Rein Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rein Therapeutics (RNTX) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Rein Therapeutics and its competitors. According to the industry distribution chart, Rein Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Rein Therapeutics' Operating Margin % too high?
Rein Therapeutics' current Operating Margin % is 0.00%. Based on the distribution chart, Rein Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rein Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' Operating Margin % compare to ATRA and OSTX?
According to the Biotechnology industry distribution chart, Rein Therapeutics ranks #999999 out of 945 companies for Operating Margin %. This places Rein Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Rein Therapeutics and its competitors. Rein Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Rein Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score
Get the complete analysis for RNTX
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNTX has been successfully added to your 
